Plazomicin Pharmacokinetics in Indian Complicated Urinary Tract Infections Patients: A Subgroup Analysis from a Phase 2 Study
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1616 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Vaishali Gupte und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Affairs, Cipla Ltd., Mumbai, India. Hauptthemen laut MEDLINE: Urinary Tract Infections, Anti-Bacterial Agents, Sisomicin. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
Multidrug–resistant Enterobacteriaceae are a primary cause of complicated urinary tract infections (cUTIs) worldwide. This study compared pharmacokinetic (PK) parameters of plazomicin among Indian versus non–India participants. This was a post hoc analysis of PK data from the Phase 2 study (ACHN–490‐002), a multicenter, double–blind, randomized, comparator–controlled study. Eligible participants (aged 18‐85 years, body weight ≤100 kg) with documented/suspected cUTI or acute pyelonephritis received either 10 or 15 mg/kg plazomicin. Among 91 participants, 70 were non–Indian and 21 were Indian. For the 15 mg/kg dose, plazomicin demonstrated a higher area under the plasma time–concentration curve from time 0 to 24 h (AUC 0‐24 ) and maximum concentration (C max ) compared to the 10 mg/kg dose, which showed greater variability. At the 10 mg/kg dose, Indian participants had a mean AUC 0‐24 of 163.0 mg•h/L, while non–Indian participants had a mean AUC 0‐24 of 185.0 mg•h/L. The estimated mean plazomicin AUC 0‐24 values were comparable between Indian and non–Indian participants. The mean C max for Indian participants was 17.2 mg•h/L, and for non–Indian participants it was 15.7 mg•h/L. Dose–normalized AUC 0‐24 and C max point estimates were 110% and 103%, respectively. This showed comparable plazomicin exposure in Indian and non–Indian patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Affairs, Cipla Ltd., Mumbai, India.
- Infectious Diseases and Infection Control, Aster Medcity, Kochi, India.
- Institute of Critical Care Medicine, Royal Care Super Specialty Hospital, Coimbatore, India.
- Department of Critical Care Medicine, Max Super Specialty Hospital, New Delhi, India.
- Critical Care, Trauma and Emergency Centre, Rajendra Institute of Medical Sciences, Ranchi, India.
- Respiratory Medicine, Critical Care and Sleep Medicine, Apollo Hospitals, New Delhi, India.
Zitieren
APA
Gupte, V., Sawant, S., Mohanasundaram, S., Malabade, R., Warrier, A., Sivakumar, M. N., Singh, Y. P., Bhattacharya, P., Chawla, R., & Gogtay, J. (2025). Plazomicin Pharmacokinetics in Indian Complicated Urinary Tract Infections Patients: A Subgroup Analysis from a Phase 2 Study. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1616
Vancouver
Gupte V, Sawant S, Mohanasundaram S, Malabade R, Warrier A, Sivakumar MN, et al. Plazomicin Pharmacokinetics in Indian Complicated Urinary Tract Infections Patients: A Subgroup Analysis from a Phase 2 Study. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1616
BibTeX
@article{Gupte2025,
author = {Gupte, Vaishali and Sawant, Sandesh and Mohanasundaram, Senthilnathan and Malabade, Rohit and Warrier, Anup and Sivakumar, M N and Singh, Yogendra Pal and Bhattacharya, Pradeep and Chawla, Rajesh and Gogtay, Jaideep},
title = {Plazomicin Pharmacokinetics in Indian Complicated Urinary Tract Infections Patients: A Subgroup Analysis from a Phase 2 Study},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1616}
}
EUVIMED